BRIEF—Sandoz says Symjepi fully stocked in the USA

Sandoz, a Novartis Division, announces that its large wholesaler customers are now fully stocked to supply hospitals and clinics with Symjepi (epinephrine) 0.3mg Injection inventory in the USA for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.

While Symjepi, a competitor to Mylan’s EpiPen (epinephrine) device, is currently available to patients through hospitals and clinics, says it is actively preparing for the US introduction of Symjepi 0.3mg and 0.15mg Injection into the retail market to enable patients to get this critical medicine at their local pharmacies.

Sandoz recently launched the Symjepi Savings Program, in which eligible patients pay as little as $0 for this life-saving medicine.

The program is, and will continue to be, distributed directly through hospital pharmacies until Symjepi is available in the retail market.

Additionally, the Symjepi website ( https://www.symjepi.com/) is live.